| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/S0025-7125(05)70004-3 |
| P698 | PubMed publication ID | 9646773 |
| P2093 | author name string | H Kaplan | |
| R L Bick | |||
| P2860 | cites work | Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C | Q24563608 |
| Deficiency of protein C in congenital thrombotic disease | Q24600822 | ||
| Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus | Q28261335 | ||
| A comparison of human prothrombin, factor IX (Christmas factor), factor X (Stuart factor), and protein S | Q28262397 | ||
| Cerebral ischemic events associated with endocarditis, retinal vascular disease, and lupus anticoagulant | Q33381987 | ||
| Anticardiolipin antibodies: isotype distribution and phospholipid specificity | Q33456927 | ||
| Changes in the blood coagulation system associated with septicemia | Q33472504 | ||
| Thrombotic Thrombocytopenic Purpura: An Extended Editorial | Q33473054 | ||
| Thrombosis or myocardial infarction in congenital clotting factor abnormalities and chronic thrombocytopenias: a report of 21 patients and a review of 50 previously reported cases. | Q33477337 | ||
| Clinical syndromes associated with lupus anticoagulants | Q33491876 | ||
| Disseminated intravascular coagulation, antiphospholipid antibodies, and ischaemic necrosis of extremities | Q33557343 | ||
| Mutation in blood coagulation factor V associated with resistance to activated protein C. | Q34340007 | ||
| Disturbed fibrinolysis in patients with inflammatory bowel disease. A study in blood plasma, colon mucosa, and faeces | Q34391659 | ||
| Monitoring warfarin therapy in patients with lupus anticoagulants | Q34434408 | ||
| Degos' disease: association with anticardiolipin antibodies and the lupus anticoagulant | Q34552474 | ||
| Hereditary protein S deficiency: clinical manifestations | Q34562831 | ||
| Familial protein S deficiency is associated with recurrent thrombosis | Q34622189 | ||
| Sublocalization of the human protein C gene on chromosome 2q13-q14. | Q34683541 | ||
| Actions and Interactions of Antithrombin and Heparin | Q35148665 | ||
| Acquired deficiencies of protein S. Protein S activity during oral anticoagulation, in liver disease, and in disseminated intravascular coagulation | Q35587970 | ||
| The factor V Leiden mutation: spectrum of thrombotic events and laboratory evaluation | Q73114776 | ||
| Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives | Q73309887 | ||
| Activated protein C resistance can be associated with recurrent fetal loss | Q73476139 | ||
| A comparison between two activated protein C resistance methods as routine diagnostic tests for factor V Leiden mutation | Q73497683 | ||
| NEUTRALIZATION OF AUTOPROTHROMBIN C ACTIVITY WITH ANTITHROMBIN | Q76849059 | ||
| INACTIVATION OF PURIFIED AUTOPROTHROMBIN I WITH ANTITHROMBIN | Q77122534 | ||
| Low protein S in essential thrombocythemia with thrombosis | Q93515627 | ||
| Comparison of progressive antithrombin activity and the concentration of three thrombin inhibitors in human plasma | Q93693722 | ||
| Effect of combined oestrogen-progestogen oral contraceptives, oestrogen, and progestogen on antiplasmin and antithrombin activity | Q93694118 | ||
| Antithrombin 3 and oestrogen content of oral contraceptives | Q93735925 | ||
| Antithrombin-3 deficiency in a Dutch family | Q36651159 | ||
| Anticardiolipin antibodies--clinical associations | Q36707524 | ||
| Detection of a new heparin-dependent inhibitor of thrombin in human plasma | Q37002723 | ||
| Abnormal plasminogen. A hereditary molecular abnormality found in a patient with recurrent thrombosis | Q37053493 | ||
| Laboratory evaluation of protein S status | Q37853769 | ||
| Laboratory diagnosis of antithrombin and heparin cofactor II deficiency | Q37931446 | ||
| Laboratory diagnosis of protein C deficiency | Q37931448 | ||
| Acquired and congenital clotting syndromes | Q37990199 | ||
| Clinical experience with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin. The Antithrombin III Study Group | Q38704387 | ||
| Heparin cofactor activity measured with an amidolytic method | Q39330305 | ||
| A new two-stage functional assay for antithrombin-III (Heparin cofactor): Clinical and laboratory evaluation | Q39397800 | ||
| Antithrombin III. Comparison of functional and immunologic assays | Q39490182 | ||
| A catalytic role for heparin. Evidence for a ternary complex of heparin cofactor thrombin and heparin | Q39496257 | ||
| Disseminated intravascular coagulation and related syndromes: a clinical review | Q39543187 | ||
| Antithrombin III deficiency | Q39550972 | ||
| Theoretic and practical considerations on laboratory monitoring of thrombolytic therapy | Q39596865 | ||
| The spectrum of neurologic disease associated with antiphospholipid antibodies. Lupus anticoagulants and anticardiolipin antibodies | Q39596940 | ||
| Fibrinolysis and atherosclerosis | Q39607819 | ||
| Platelet antithrombin deficiency: a new clinical entity | Q39631983 | ||
| Structural and functional characterization of factor XII. | Q39762692 | ||
| Heparin cofactor II and other endogenous factors in the mediation of the antithrombotic and anticoagulant effects of heparin and dermatan sulfate | Q39828321 | ||
| Natural Inhibitors of the Coagulation System | Q40105421 | ||
| Protein S and the Regulation of Activated Protein C | Q40117533 | ||
| Protein C Activation | Q40143316 | ||
| Clinical studies of protein C. | Q40181163 | ||
| Seminars in Thrombosis and Hemostasis | Q40206727 | ||
| Clinical hemostasis practice: the major impact of laboratory automation | Q40208629 | ||
| Structure and function of protein C. | Q40212752 | ||
| Clinical relevance of antithrombin III. | Q40249876 | ||
| Laboratory evaluation of antithrombin III: a critical overview of currently available methods for antithrombin III measurements | Q40267177 | ||
| The antiphospholipid and thrombosis (APL-T) syndromes. Clinical and laboratory correlates. | Q40544880 | ||
| Laboratory diagnosis of antiphospholipid syndromes. | Q40544886 | ||
| Antiphospholipid antibodies in coronary artery disease: a review | Q40688222 | ||
| Neurological syndromes associated with antiphospholipid antibodies | Q40688233 | ||
| Cutaneous expressions of antiphospholipid syndromes | Q40688246 | ||
| Antithrombin III in fresh and cultured human endothelial cells: A natural anticoagulant from the vascular endothelium | Q41101978 | ||
| Production of plasminogen activator by alveolar macrophages in normal subjects and patients with interstitial lung disease | Q41131063 | ||
| Association between alveolar macrophage plasminogen activator activity and indices of lung function in young cigarette smokers | Q41260460 | ||
| Behavior of protein S during long-term oral anticoagulant therapy | Q41358518 | ||
| Activated protein C resistance due to a common factor V gene mutation is a major risk factor for venous thrombosis | Q41360432 | ||
| Antiphospholipid thrombosis syndromes: etiology, pathophysiology, diagnosis and management | Q41441142 | ||
| Anticoagulant activity of heparin: Separation of high‐activity and low‐activity heparin species by affinity chromatography on immobilized antithrombin | Q42102840 | ||
| Successful treatment of homozygous protein C deficiency by hepatic transplantation | Q42730769 | ||
| Changes in antithrombin 3 and plasminogen induced by oral contraceptives | Q43495926 | ||
| Long-term treatment with combined oral contraceptives and cigarette smoking associated with impaired activity of tissue plasminogen activator | Q43573359 | ||
| The Fibrinolytic System in Patients with Diabetes mellitus with Special Reference to Diabetic Retinopathy | Q44019818 | ||
| Coagulation abnormalities in patients with precocious coronary artery thrombosis and patients failing coronary artery bypass grafting and percutaneous transcoronary angioplasty | Q44121126 | ||
| Identification of two distinct heparin cofactors in human plasma. Separation and partial purification | Q44241360 | ||
| Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis | Q44390738 | ||
| Fibrinolytic Activity in Acute Myocardial Infarction | Q44539357 | ||
| Heparin cofactor II in adults and infants with thrombosis and DIC. | Q44881385 | ||
| Anticardiolipin antibodies and lupus anticoagulants comprise separate antibody subgroups with different phospholipid binding characteristics. | Q45239170 | ||
| Antithrombin 3 and the estrogen content of combined estro-progestagen contraceptives | Q45281196 | ||
| Resistance to activated protein C in unselected patients with arterial and venous thrombosis | Q45882491 | ||
| Deep Vein Thrombosis: Prevalence of Etiologic Factors and Results of Management in 100 Consecutive Patients | Q46010793 | ||
| Identification of two distinct heparin cofactors in human plasma. II. Inhibition of thrombin and activated factor X. | Q47828354 | ||
| Fundamental interactions and effect of storage, ether, adsorbants and blood clotting on plasma antithrombin activity. | Q51041857 | ||
| The interaction of thrombin and heparin. Proflavine dye binding studies. | Q52889373 | ||
| The molecular mechanisms of heparin action: II. Separation of functionally different heparins by affinity chromatography | Q54062964 | ||
| Fibrinogen Detroit--a molecular defect in the N-terminal disulphide knot of human fibrinogen? | Q55061969 | ||
| Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening | Q56172386 | ||
| Widespread cutaneous necrosis in a patient with rheumatoid arthritis associated with anticardiolipin antibodies | Q57733164 | ||
| Factor XII activity and antigen concentrations in patients suffering from recurrent thrombosis | Q58962276 | ||
| Inherited Antithrombin Deficiency Causing Thrombophilia | Q64386294 | ||
| Coagulation Abnormalities in Liver Disease | Q66847465 | ||
| Inactivation and binding of human plasma kallikrein by antithrombin III and heparin | Q66889398 | ||
| Heparin Interaction with Activated Factor X and Its Inhibitor | Q66920924 | ||
| Antithrombin III in adolescents | Q66950538 | ||
| Inhibition of thrombin by antithrombin III in the presence of certain glycosaminoglycans found in the mammalian aorta | Q67017849 | ||
| Acquired antithrombin III deficiency and thrombosis in the nephrotic syndrome | Q67401636 | ||
| Characterization of human, bovine, and horse antithrombin III | Q67434217 | ||
| Antithrombin in infancy and childhood | Q67510846 | ||
| Disseminated intravascular coagulation | Q67594376 | ||
| Antithrombin III(AT-III) as a diagnostic aid in disseminated intravascular coagulation | Q67596968 | ||
| Radiolabelled ATIII as a probe for the detection of activation of blood coagulation in vivo | Q67800659 | ||
| Platelet lipoxygenase defect (Wien-Penzing defect) in two patients with myocardial infarction | Q67983922 | ||
| Inactivation of heparin cofactor II by polymorphonuclear leukocytes | Q68208379 | ||
| Anticardiolipin antibodies in HIV infected patients with or without immune thrombocytopenic purpura | Q68284105 | ||
| Procoagulant and Plasminogen Activator Activities of Bronchoalveolar Fluid in Patients with Pulmonary Sarcoidosis | Q68364151 | ||
| Lipoprotein(a) inhibition of plasminogen activation by tissue-type plasminogen activator | Q68409750 | ||
| Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis | Q68431534 | ||
| Heparin cofactor II: a simple assay method and results of its clinical application | Q68524702 | ||
| Cerebral thromboembolism due to antithrombin III deficiency in two children | Q68971425 | ||
| Low heparin cofactor II associated with abnormal crossed immunoelectrophoresis pattern in two Norwegian families | Q69006438 | ||
| Familial hypofibrinolysis and venous thrombosis | Q69186403 | ||
| Simultaneous lupus anticoagulant and anticardiolipin assays and clinical detection of antiphospholipids | Q69218161 | ||
| Recurrent thrombosis and renal vascular disease in patients with a lupus anticoagulant | Q69268396 | ||
| Acute promyelocytic leukemiaA model for understanding the role of the malignant cell in hemostasis | Q69358006 | ||
| Incidence of increased plasminogen activator inhibitor in patients with deep venous thrombosis and/or pulmonary embolism | Q69421500 | ||
| Arterial thrombosis in antithrombin III deficiency | Q69615998 | ||
| Severe Guillain-Barré syndrome: an association with IgA anti-cardiolipin antibody in a series of 92 patients | Q69833176 | ||
| Constitutional heparin co-factor II deficiency associated with recurrent thrombosis | Q69868743 | ||
| Effects of moderate alcohol consumption on platelet aggregation, fibrinolysis, and blood lipids | Q69900158 | ||
| Platelet hyperaggregability in patients with chest pain and angiographically normal coronary arteries | Q70024188 | ||
| Oral contraceptives reduce total protein S, but not free protein S | Q70026840 | ||
| Protein S deficiency occurs in the nephrotic syndrome | Q70031609 | ||
| High level of protein C and protein S in nephrotic syndrome | Q70032787 | ||
| Total and free protein S in nephrotic syndrome | Q70048939 | ||
| The effects of oestrogen administration on the plasma free protein S and C4b-binding protein | Q70055247 | ||
| Plasma concentrations of C4b-binding protein and vitamin K-dependent protein S in term and preterm infants: low levels of protein S-C4b-binding protein complexes | Q70055605 | ||
| The levels of protein C and protein S in plasma in patients with type II diabetes mellitus | Q70068894 | ||
| Assignment of the human antithrombin III structural gene to chromosome 1q23-25 | Q70071266 | ||
| Optic neuritis and myelopathy in systemic lupus erythematosus | Q70292559 | ||
| Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report | Q70394883 | ||
| Alteration in Fibrinolysis Associated With Surgery and Venous Thrombosis | Q70493539 | ||
| Urokinase inhibitors in serum in a clinical series | Q70523616 | ||
| Antithrombin III concentrate as adjuvant in DIC treatment. A pilot study in 9 severely ill patients | Q70632539 | ||
| Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn | Q70811173 | ||
| Assay of dermatan sulfate cofactor (heparin cofactor II) activity in human plasma | Q70814658 | ||
| Abnormal plasminogen, a case of recurrent thrombosis | Q70890388 | ||
| Antithrombin III patterns in disseminated intravascular coagulation | Q71175179 | ||
| Congenital protein C deficiency and venous thromboembolism. A study of three Dutch families | Q71245149 | ||
| A functional assay for protein C in human plasma | Q71248543 | ||
| Binding of thrombin to antithrombin III | Q71301884 | ||
| At III content and antithrombin in activity in oestrogen-progestogen and progestogen-only treated women | Q71317492 | ||
| Immunochemical analysis of active and inactive antithrombin III | Q71520193 | ||
| The antiphospholipid-thrombosis syndromes. Fact, fiction, confusion, and controversy | Q72630585 | ||
| Hereditary thrombophilia among 217 consecutive patients with thromboembolic disease in Jordan | Q72671658 | ||
| Inhibition of thrombin-induced platelet aggregation and serotonin release by antithrombin III and heparin cofactor II in the presence of standard heparin, dermatan sulfate and pentosan polysulfate | Q72744367 | ||
| Identification of heparin cofactor II as the principal plasma cofactor for the antithrombin activity of pentosan polysulphate (SP54) | Q72751957 | ||
| The influence of factor VIII on measurement of activated protein C resistance | Q73076141 | ||
| P433 | issue | 3 | |
| P921 | main subject | thrombosis | Q261327 |
| thrombophilia | Q1570013 | ||
| P304 | page(s) | 409-458 | |
| P577 | publication date | 1998-05-01 | |
| P1433 | published in | Medical Clinics of North America | Q15761972 |
| P1476 | title | Syndromes of thrombosis and hypercoagulability. Congenital and acquired causes of thrombosis | |
| P478 | volume | 82 |
| Q33670367 | Antibodies to serine proteases in the antiphospholipid syndrome |
| Q34430433 | Antiphospholipid thrombosis syndromes |
| Q73103175 | Antiphospholipid thrombosis syndromes |
| Q36277248 | Antithrombotic therapy for stroke in young adults |
| Q35783732 | Argatroban therapy for antithrombin deficiency and mesenteric thrombosis: case report and review of the literature |
| Q34169023 | Cerebral infarctions in the fetus and neonate: maternal-placental-fetal considerations |
| Q52535636 | Evaluation of a modified arrow-trerotola percutaneous thrombolytic device for treatment of acute pulmonary embolus in a canine model. |
| Q34054479 | Evaluation of the hypercoagulable state. Whom to screen, how to test and treat |
| Q49103292 | Factor V Leiden mutation and other thrombophilia markers in childhood ischemic stroke |
| Q36481556 | Hereditary and acquired thrombophilic disorders |
| Q28222248 | Imaging diagnosis--aortic thromboembolism associated with spirocercosis in a dog |
| Q44924702 | In-vitro evaluation of a new inferior vena cava filter-the stent-filter. |
| Q43917560 | Initial experiences with point-of-care rapid thrombelastography for management of life-threatening postinjury coagulopathy |
| Q73389256 | Is testing for inherited coagulation inhibitor deficiencies in young stroke patients worthwhile? |
| Q42936484 | Malignant hemispheric cerebral infarction associated with idiopathic systemic capillary leak syndrome |
| Q36851081 | Pharmacogenetic typing for oral anti-coagulant response among factor V Leiden mutation carriers. |
| Q34059375 | Proficient and cost-effective approaches for the prevention and treatment of venous thrombosis and thromboembolism |
| Q37283026 | Some antiphospholipid antibodies bind to hemostasis and fibrinolysis proteases and promote thrombosis. |
| Q39649616 | Suspected Pulmonary Artery Disruption after Transvenous Pulmonary Embolectomy Using a Hydrodynamic Thrombectomy Device: Clinical Case and Experimental Study on Porcine Lung Explants |
| Q33832002 | The caput medusae of hypercoagulability |
| Q35081863 | Thromboprophylaxis and thrombosis in medical, surgical, trauma, and obstetric/gynecologic patients |
| Q28193706 | Treatment and monitoring of patients with antiphospholipid antibodies and thrombotic history (Hughes syndrome) |
Search more.